Session Abstract – PMWC 2025 Silicon Valley

Showcase Track S2 - February 5 11.00 A.M.-4.45 P.M.,Showcase Track S2 - February 6 9.15 A.M.-4.45 P.M.,Showcase Track S2 - February 7 11.00 A.M.-1.30 P.M.


The PMWC 2025 Data Applications in Clinical Diagnostics Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Neurodegenerative


Confirmed Presenting Companies:

 Speaker Profile

Ph.D., MBA, President & CEO, Moleculera

Biography
Craig Shimasaki has over 35 years of experience in the biotechnology industry and started his career at Genentech. He co-founded several companies, led multiple products through the FDA approval process. His passion is to help translate scientific and medical discoveries into acutely needed products so that more patients can live healthier lives. He is a co-inventor on multiple patents and his company's work spans bench-to-bedside, including epitope mapping for an HIV vaccine, genetic breast cancer risk prediction biomarkers, a rapid influenza diagnostic, and therapeutics for infectious diseases, neuropsychiatric disorders, and noise-induced hearing loss. Dr. Shimasaki received his BS in biochemistry from the University of California at Davis, his PhD in molecular biology from the University of Tulsa, and his MBA from Northwestern University's Kellogg School of Business. He is an Adjunct Professor at the University of Oklahoma and teaches biotechnology entrepreneurship.


Talk
Precision Medicine Approach to Testing for Immune-Mediated Neuropsychiatric Disorders
Moleculera Biosciences detects brain-directed, immune-mediated autoantibodies in patients suffering from commonly known neurologic, psychiatric, and behavioral disorders. Patients suffering from schizophrenia, autism, PANSPANDAS, and others, benefit from a precision medicine approach as test-postive patients respond to immune modulators and anti-inflammatory therapies. Our 15,000 biobank is used for the development of follow-on products and treatment targets.


Clinical Dx Showcase:
Moleculera

Moleculera Biosciences performs a blood panel that identifies immune-mediated neuropsychiatric and mental disorders. This Autoimmune Brain Panel detects serum autoantibodies targeting specific brain markers, which guide physicians to highly effective anti-inflammatory and immune modulatory treatments that resolve the underlying cause rather than ineffectively treating symptoms.

 Speaker Profile

Ph.D., CEO & Chairman, Novigenix SA

Biography
Brian Hashemi is cofounder and Executive Chairman of Novigenix. A former NASA Principal Investigator and Researcher, Dr. Hashemi has extensive background in healthcare technology development and commercialization and has been an Assistant Professor at Baylor College of Medicine where he began his affiliation in the National Space Biomedical Research Institute. Brian holds a Ph.D. in Applied Physics from Cornell University in New York, and an MBA in Entrepreneurship from the Wharton School in Philadelphia.


Clinical Dx Showcase:
Novigenix

Novigenix is a precision oncology biotech with a proprietary platform LITOseek optimized for mapping the response of the immune system to onset and progression of disease to provide actionable insights and precision solutions for optimization of patient’s therapeutic journey.

 Speaker Profile

Ph.D., VP of Research, Complete Genomics

Biography
Dr. Yuan Jiang is the Vice President of Research with over a decade of experience in genomic technology development and commercialization. An expert in genomics, molecular biology, and NGS, Dr. Jiang has successfully led cross-functional teams in the creation of cutting-edge products, from concept through to market. She has been instrumental in launching key NGS and molecular diagnostic tools, including spatial genomics, NGS applications and CRISPR-Cas technologies. With a Ph.D. in Genetics from Cornell University, Dr. Jiang is a proven innovator and leader, holding several patents in advanced genomic methodologies. Her work continues to drive advancements in genomic science and its practical applications.


Talk
Mapping the Future: How Stereo-seq Accelerates Multi-Omics Discovery
Stereo-seq is a groundbreaking spatial transcriptomics technology enabling high-resolution, species agnostic, whole transcriptomics mapping across tissue sections. By integrating multiomics, it provides unparalleled insights into cellular heterogeneity, spatial organization, and molecular interactions within tissues. This approach advances our understanding of complex biological processes, such as cancer progression and immune response, facilitating precision medicine.


Spatial Showcase:
Complete Genomics

Complete Genomics is a pioneering life sciences company, founded in 2005, offering a comprehensive portfolio including sample extraction, library preparation, lab automation, and sequencing platforms. Our mission is to drive genomics forward with complete sequencing solutions that improve lives.

 Speaker Profile

Ph.D., Vice President, Business Development, Biodesix

Biography
Matthew Pink has over 14 years of experience in the pharma and diagnostics industries. He leads the biopharma services division at Biodesix, Inc. He previously served as Director of Business Development at CSL Behring followed by U.S. Director of Research External Innovation. Matthew has a B.S. in Biology from the University of Wisconsin-Madison and a Ph.D. in Neuroscience from the University of Colorado.


Talk
Guiding Therapeutic Development with Ultrasensitive, Cost-effective ctDNA Monitoring
Trends in the use of ctDNA in clinical trials to support refinement of dosage and surrogate intermediate endpointsTechnology features to consider for longitudinal ctDNA monitoring Benefits of Droplet Digital PCR (ddPCR) in prospective and retrospective clinical trials


Clinical Dx Showcase:
Biodesix

At Biodesix, we are your dedicated partner throughout the entire diagnostic journey, from biomarker discovery to assay development, verification, and validation to clinical trial sample testing through to test commercialization. We offer a comprehensive suite of services to turn your therapeutic development into tangible results.

 Speaker Profile

CTO, Genomill Health

Biography
Manu Tamminen is an expert in molecular biology, next generation DNA sequencing and bioinformatics. He received his PhD from the University of Helsinki and did his postdoctoral research at MIT and ETH Zürich, where he developed methodologies for single cell sequencing and molecular counting. He is currently an Adjunct Professor and Academy Fellow at the University of Turku and has authored several high impact research publications.


Talk
Novel Precision Diagnostics Using Circular DNA
DNA sequencing has evolved, but sample preparation remains outdated, driving high costs, noisy data, and complex tests. We've revolutionized this process with circular DNA technology, delivering unmatched cost-efficiency, simplicity, and data quality for next-generation sequencing.


Clinical Dx Showcase:
Genomill Health

Genomill Health is a pioneering precision diagnostics company with a mission to make molecular diagnostics more scalable, sensitive and accessible for all.

 Speaker Profile

M.D., CEO and Co-founder, Inmedix

Biography
Andrew Holman is a clinical rheumatologist who discovered and published the role of dopamine agonists (Parkinson's disease medications) as a leading treatment for fibromyalgia (FM). This work, combined with the immunology training of rheumatology, led to exploration of how stress impacts autoimmune disease onset, activity, treatment response and potential remission. The concept is called immuno-autonomics and it is revolutionizing how doctors address stress biology, first in autoimmune disease, and next, in other diseases adversely impacted by stress.


Talk
Precision Medicine: Predictive HRV Stress Diagnostics for Autoimmune Disease
Precision medicine helps us understand why patients respond differently to the same treatment. A Stress biology diagnostics explain much of this conundrum and have been validated to enable far superior therapeutic outcomes and reduce cost and waste.


Clinical Dx Showcase:
Inmedix

Seattle-based Inmedix is bringing next-generation heart rate variability (HRV) to clinicians on a high-fidelity ECG platform with data analyzed in real-time in the cloud.

 Speaker Profile

M.D., Ph.D., Chief Medical Officer, Velsera

Biography
Dr. Nagarajan has been a pioneer in genomics and informatics for 20+ years. He started at Washington University, the first CAPCLIA laboratory for clinical NGS, and where he facilitated clinical and translational research by integrating EHR, clinical trials, patient registry, biospecimen, and genomics data and by supporting complex multimodal analyses across these data types. As the Founder and President of Pierian, he built the Clinical Genomics Workspace (CGW), an endtoend disease, assay and instrument agnostic informatics solution used to process clinical NGS cases. At Velsera, Dr. Nagarajan leads the Knowledgebase team, which is responsible for curated clinical content that supports tertiary analysis in the CGW, and is responsible for regulatory submissions and for incubating and developing technology solutions to extend Velseras reach.


Talk
Analytics Insights for IVD Development and Delivery
A flexible platform is needed for analysis and interpretation of multimodal datasets, enabling biomarker discovery and characterization and subsequent IVD design. Similarly, a regulated platform is needed to support IVD development, validation, and delivery. We will present how Velseras cloud platform and services may be leveraged to achieve these goals. has context menu


Clinical Dx Showcase:
Velsera

Velsera connects healthcare and life sciences to reveal the true promise of precision medicine—a continuous flow of knowledge between researchers, scientists and clinicians around the world, creating insights that radically improve human health.

 Speaker Profile

Global Head, Commercial Precision Medicine Strategy, Johnson & Johnson

Biography
Neha Kumar is passionate about transforming healthcare, and has a 15+ year track record of building organizations that launch innovative healthcare products and drive change across the healthcare ecosystem. She currently leads Global Commercial Strategy for Precision Medicine at JJ, focusing on precision medicine beyond oncology. Prior to JJ, Neha founded a consulting firm supporting startups in genomics, digital health, and health data. Before that, Neha was VP New Markets and Commercial at Invitae, and VP of Global Marketing at CooperSurgical. She joined CooperSurgical following the acquisition of Recombine, where she was Chief Product Officer and founding employee.


Talk
A New Era: Precision Medicine in Women's Health
It's time for precision medicine in women's health - starting with alloimmune disorders of pregnancy, HDFN and FNAIT. How can we bring together advanced diagnostics with therapeutic innovation to bring about an era of precision medicine in women's health?


Clinical Dx Showcase:
JnJ

 Speaker Profile

Ph.D., CEO, MyOme

Biography
Premal Shah, Ph.D., is the CEO of MyOme, a genomics innovation company focused on preventive health through whole genome sequencing and polygenic risk scoring. With over 20 years of experience in biotech and healthcare, he is dedicated to advancing personalized medicine and genomics-driven health solutions. Previously, Premal was Co-Founder President at Ciitizen, a digital health company empowering patients with their own health data, where he oversaw operations and strategic development, including go-to-market strategies. Ciitizen was acquired by Invitae. Before Ciitizen, he served as CEO of Applied Proteomics, a company pioneering a blood-based colorectal cancer diagnostic test. Prior to that, he led corporate development at Genomic Health (now part of Exact Sciences). Premal began his career as a management consultant at Booz Company, focusing on front-office strategies. He holds a Ph.D. in computational biology from the California Institute of Technology, with several publications in the field.


Talk
Advancing Breast Cancer Risk Assessments with Natera
MyOmes Breast Cancer Polygenic Risk Score (PRS) introduces a next-gen approach to breast cancer risk by integrating PRS with clinical factors, and has been validated across diverse populations. iPRS is currently used with Nateras Empower test and Alabamas Catalyst program, with these case studies to be presented.


Clinical Dx Showcase:
MyOme

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies.

 Speaker Profile

Ph.D., Founder, Travera

Biography
Dr. Reid is a serial entrepreneur focused on precision medicine. He founded Complete Genomics (GNOM: NASDAQ), a DNA sequencing company that revolutionized whole human genome sequencing (now part of MGI), and Travera, and cancer therapy selection company that is revolutionizing the way oncologists select effective drugs for their patients. Prior to Complete Genomics he founded two enterprise software companies, Eloquent (ELOQ: NASDAQ), an internet video company, and Verity (VRTY: NASDAQ), an enterprise search engine company.


Talk
Personalizing Therapies When Biomarkers Fail
Cancer therapies that cure cancer or achieve decades of remission have eluded cancer researchers and drug developers for all by a tiny fraction of cancer patients. An alternative approach to therapy selection may offer durable therapeutic response for most cancer patients.


Clinical Dx Showcase:
Travera

Travera uses a unique non-genomic technology to measure the response of live cancer cells to cancer drugs. Its 2-day CLIA-certified test enables oncologists to select effective therapies for their late-stage patients who are out of good options.

 Speaker Profile

Ph.D., Chief Scientific Officer, AOA Dx

Biography
At AOA, Abby is responsible for strategic management and technical oversight of all of AOA's product offerings, spanning the product lifecycle from research to commercial manufacturing. Abby has nearly two decades of oncology diagnostics experience, including leadership roles at Roche Tissue Diagnostics (Ventana), Thrive (Exact Sciences) and PGDx (LabCorp). She has overseen RD, regulatory submissions, and product launches, including IHC-based companion diagnostics, NGS panels, and ML-enabled multi-omic assays for early cancer detection. Abby specializes in uniting science, teams, and tech to develop impactful diagnostic systems.


Talk
Lipid Profiling for Ovarian Cancer Early Detection
Ovarian cancer (OC) is diagnosed at late stages due to ineffective diagnostics. Lipids are promising cancer biomarkers, and technology has advanced to utilize them clinically. We describe our approach using lipids, proteins and machine learning to develop a diagnostic OC assay. We discovered molecular signatures that distinguish OC in symptomatic and asymptomatic populations.


Clinical Dx Showcase:
AOA Dx

AOA Dx is a biotech company revolutionizing early cancer detection for women, starting with ovarian cancer. Using multi-omics and advanced computational biology, their platform enables non-invasive diagnostics to identify cancer early, improving survival rates and patient outcomes.

 Speaker Profile

M.D., Chief Medical Officer, Chief Quality Officer, Baylor Genetics

Biography
Dr. Christine Eng serves as the Chief Medical Officer and Chief Quality Officer at Baylor Genetics. In addition to her role at Baylor Genetics, Dr. Eng is a Professor at Baylor College of Medicine in Houston, TX, as well as a pediatrician, and medical geneticist. As a winner of the 2024 Modern Healthcare Women Leaders in Healthcare award, Dr. Eng is recognized for several contributions to the implementation of genomics in clinical practice. She serves as principal investigator of the genome sequencing core for the National Institutes of Healths Undiagnosed Diseases Network and was elected to the Board of Directors of the American Society of Human Genetics effective January 1, 2024. Dr. Eng received her bachelors degree from Yale University. Following her bachelors, she received her medical degree from Tulane University.


Talk
RNA Sequencing to Help Identify Rare Genetic Disorders
RNA sequencing to help identify and diagnose rare genetic disorders.


Clinical Dx Showcase:
Baylor Genetics

Baylor Genetics provides diagnostic answers to complex medical conditions and rare diseases. The company specializes in rapid Whole Genome Sequencing and Whole Exome Sequencing and complementary panels. Baylor Genetics works to transform healthcare and improve lives by converting scientific innovations into accessible clinical solutions.

 Speaker Profile

Co-Founder & CEO, OneCell Dx

Biography
Mohan Uttarwar is an accomplished entrepreneur and innovator with extensive expertise in life sciences and precision diagnostics. With a strong track record of building successful companies, he has pioneered advancements in healthcare through innovative technologies and transformative solutions. Mohans work focuses on addressing unmet needs in oncology and personalized medicine, leveraging cutting-edge platforms to improve patient outcomes.As a visionary leader, he excels in driving strategic growth, fostering collaborations, and guiding teams to achieve breakthrough results. His contributions have significantly influenced the development of next-generation diagnostic tools, particularly in the areas of liquid biopsy and multiomics.Mohan remains committed to advancing healthcare by bridging the gap between scientific discovery and clinical application, creating impactful solutions for patients and healthcare providers worldwide.


Talk
Cell Biopsy A.I. Shaping the Future of Precision Oncology
Discover how Cell Biopsy and Artificial Intelligence are revolutionizing Precision Oncology. This talk highlights innovations in liquid biopsy, single-cell analysis, and AI-powered insights, driving real-time tumor profiling and personalized therapies. Gain insights into how these technologies will shape cancer care and advance treatment outcomes.


Clinical Dx Showcase:
OneCell Dx

OneCell Diagnostics is a Precision Oncology company revolutionizing cancer care through advanced liquid biopsy solutions. Its cutting-edge platform integrates single-cell multiomics to deliver real-time tumor insights, empowering personalized therapies and accelerating breakthroughs in clinical research.

 Speaker Profile

M.D., M.Phil., Regional Director and Assoc. Chief, Kaiser

Biography
Dr. Manace is a practicing medical geneticist, KP Northern California Regional Director for Precision Medicine Genomics, and Associate Chief for Regional Genetics Screening Tracking where she leads multidisciplinary teams through transformational change in genetic care delivery. Dr. Manaces research focuses on innovation in delivery science, and she is a member of the Kaiser Permanente Northern California Investigational Review Board and Co-Chair for Research Quality and Compliance. She is an Assistant Clinical Professor at the University of California, San Francisco. She has published and spoken on scientific, ethical legal and social implications, and heath information technology in Clinical Genetics and Genomic Medicine in the US and internationally.


Talk
While there is ample evidence and literature to support mainstreaming genomics for equitable access across diverse populations, the culture change and logistics raises significant barriers, even in medical organizations centered around prevention and total health. By breaking the components into manageable segments, more can access the clinical and financial benefits of personalized medicine.


Clinical Dx Showcase:
Kaiser Permanente

The Permanente Medical Group is a physician-lead group practice contracting with the Kaiser Hospital and Health Plan Foundation to deliver primary to quaternary care across 4.5 million members in Northern California.

 Speaker Profile

M.D., FCAP, Medical Director, Companion Diagnostics and Advanced Assays, Leica Biosystems

Biography
Dr. Baumann is a board-certified anatomic and clinical pathologist who is currently Medical Director of Companion Diagnostics and Advanced Assays at Leica Biosystems. Prior to her current role she was a pathologist and medical director at Roche Tissue Diagnostics and AstraZeneca. Her practice focus is companion diagnostic assay development and commercialization, and digital pathology algorithm development and clinical deployment.


Talk
Why Computational Pathology is Key to Precision Diagnostics
Discover how computational pathology is revolutionizing precision diagnostics. This presentation explores challenges with manual scoring methods, the benefits of AI-powered computational pathology, and its transformative role in improving biomarker quantification, enabling personalized therapies, and accelerating drug development. Learn how adopting computational pathology can translate to better patient outcomes.


Clinical Dx Showcase:
Leica Biosystems

Leica Biosystems is a global leader in cancer diagnostics with one of the most comprehensive portfolios from biopsy to diagnosis. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.

 Speaker Profile

Founder & CEO, Eaze Bio

Biography
Reem Mahrat, Founder of Eaze Bio, is a biotech visionary advancing womens health through innovative diagnostics and therapies. She also leads EGE, transforming healthcare with precision medicine and epigenetic gene editing. Previously, she successfully scaled and exited RamanID and Calico Bio Labs. As Entrepreneur in Residence at Daybreak Labs, Reem mentors emerging innovators, fostering breakthroughs in diagnostics and therapeutics. A passionate advocate for equity, her upcoming book empowers readers to take control of their health.


Talk
Revolutionizing Womens Health: Precision Medicine Meets Empowerment
Discover how Eaze Bio is pioneering next-generation diagnostics to transform womens health. Founder Reem Mahrat highlights innovative approaches addressing unmet needs, from early detection to precision therapies, empowering women with cutting-edge solutions that redefine the future of personalized healthcare and advance equity in wellness worldwide.


Clinical Dx Showcase:
Eaze Bio

Eaze Bio revolutionizes women’s health with next-generation diagnostics and precision medicine. Focused on early detection and personalized solutions, the company empowers women globally by addressing critical healthcare gaps with cutting-edge innovation and compassion.

 Speaker Profile

M.D., Ph.D., Professor, UCSF

Biography
Mekhail Anwar, MD, PhD, physician-scientist and Professor in Radiation Oncology at UCSF and Electrical Engineering at UC Berkeley, is developing fundamentally new approaches to guide cancer therapy at the cellular level by creating technology platforms effectively placing the physician inside the patient. Key to these efforts is the introduction of integrated circuits (computer chips) to biological detection, moving beyond electrical interfaces to communicate with molecules and cells - the fundamental drivers of disease states.Building on his early work in chip-scale imagers to enhance surgical precision, supported by the DoD and NIH, he leads a ARPA-H project advancing his VISION imaging platform into the clinic. Supported by the NIHs New Innovator Award, he creates chip-scale implants that visualize real-time tumor responses to immunotherapy from within the tumor itself.He received his BA in Physics from UC Berkeley, graduating as the University Medalist (valedictorian), PhD in Electrical Engineering from MIT and MD residency from UCSF.


Talk
Guiding Cellular Scale Cancer Care using Integrated Circuits in-Vivo
The inability to visualize cancer at cellular scale in patients is a fundamental roadblock to treating cancer. We will discuss personalizing therapy through (1) guiding cancer surgery at the single cell level and (2) the development of new integrated circuit-based platforms for monitoring - and adapting - the real-time tissue response to immunotherapy.


Clinical Dx Showcase:
UCSF

UCSF and UCB provide a synergistic combination of medical and engineering innovation to enable us to create novel integrated circuits to fundamentally change how we treat cancer.

 Speaker Profile

Ph.D., CEO & Co-Founder, Cordance Medical

Biography
Bhaskar Ramamurthy is an expert in designing and developing medical devices, especially ultrasound medical devices, optical devices, and robotics devices. He has over 40-50 patentspatent applications to his name. He has worked for small and large multinational companies, rising from entry-level engineer to Director, Vice-President, Chief Technical Officer, and now founder and Chief Executive Officer. Bhaskars expertise includes medical device project management, program management, and risk management, including identification and mitigation, conducting preclinical and clinical studies, and developing robust development and implementation strategies. He is also an expert in developing intellectual property and patenting strategies.


Talk
Plasma-based Precision Medicine in Neurology with Focused Ultrasound
The blood-brain barrier prevents the use of plasma-based liquid biopsy in brain diseases. Focused ultrasound can temporarily increase the permeability of the BBB, enabling liquid biopsy by letting disease biomarkers enter the circulatory system from the brain. Blood can be collected from the arm, and the biomarkers can be analyzed.


Clinical Dx Showcase:
Cordance Medical

Cordance Medical is developing a patient-friendly, noninvasive, focused ultrasound device that can temporarily and safely open the blood-brain barrier. The device is designed to be portable, economical, and widely deployable in space-constrained environments like infusion centers and community clinics.

 Speaker Profile

Ph.D., CEO & Co-Founder, Allelica Inc

Biography
Giordano Botta is the Co-Founder and CEO of Allelica Inc, where he drives the development and clinical implementation of multi-ancestry polygenic risk scores (PRS). Under his leadership, Allelica pioneered the first clinical multi-ancestry PRS test for Coronary Artery Disease (CAD), breast and prostate cancer, now used by leading healthcare systems. He focuses on cost-effectiveness analysis to ensure the long-term sustainability of PRS tests. Botta has overseen the creation of a software engine and the integration of genomic and clinical data from over one million individuals of diverse ancestries to develop and validate PRS. His primary interest is advancing the integration of PRS for CAD and common cancers into standard medical care, improving prevention and early intervention strategies.


Talk
Multi-Ancestry Polygenic Risk Score for Heart Attack Prevention
Heart attacks, the leading cause of death, are highly preventable, yet 30% occur in individuals without traditional risk factors. This talk presents care pathways using PRS to identify high-risk individuals invisible to the standard of care. A new method to enhance accuracy in risk assessment across ancestries, without relying on predefined labelling, will be discussed.


Clinical Dx Showcase:
Allelica Inc

Allelica specializes in multi-ancestry polygenic risk scores (PRS) to predict risk for common diseases. Its advanced diagnostics empower physicians and healthcare systems to reduce disease burden, supported by major publications, five patents and endorsements from key opinion leaders.

 Speaker Profile

M.D., Ph.D., Associate Professor of Medicine, MayoClinic / Phenomix

Biography
Dr. Acosta is a physician, scientist, inventor, and entrepreneur. Board certified in Internal Medicine, Gastroenterology, and Obesity Medicine. He is an Associate Professor of Medicine and co-directs the Nutrition Obesity Research Program at the Mayo Clinic. His research focus on precision medicine for obesity with the aim to identify the right therapy for the right patient. His research is supported by the NIH, many foundations and industry. He is a recognized national and international speaker with many patents, more than 160 peer-reviewed publications, including publications in the Lancet, Gut and Gastroenterology, and many chapters. His works has been featured in the New York Times, Time, NPR, among others. He won the 40-under-40 innovation award at Minneapolis Business Journal and Tekne Award. He co-founded Phenomix Sciences and launched the first-of-its-kind diagnostic test to predict response to GLP-1s and other obesitymetabolic interventions. Time Magazine selected as one of the best inventions of 2024.


Talk
Machine-learning Assisted Gene Risk Score Predicts Response to GLP-1s
The response to GLP-1s is highly variable. We created a Machine-learning Assisted Gene Risk Score Predicts Response to GLP-1s and other obesity and metabolic interventions. This first-of-its-kind diagnostic test, called MyPhenome, was launched in 2024.


Clinical Dx Showcase:
MayoClinic / Phenomix

Phenomix Sciences is a AI-enabled Precision Medicine for Obesity and Metabolic Diseases.

 Speaker Profile

Ph.D., Vice President, Head of Science, Oncology, Labcorp

Biography
Taylor Jensen joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on cell-free DNA in the U.S. Subsequently, Dr. Jensen was involved in numerous development efforts focused on the detection of genomic and epigenomic changes in cfDNA for use in prenatal and cancer diagnostics. Since the acquisition of Sequenom by LabCorp in 2016, his work has been primarily focused on biomarkers, precision medicine diagnostic assays, and product strategy with the overarching goal of utilizing these technologies to improve human health. He is a member of multiple professional societies including AACR and ASCO, has contributed to multiple awarded patents, and has authored or co-authored more than 35 publications in peer reviewed scientific journals. He holds a Ph.D. in Pharmacology and Toxicology from the University of Arizona and was a postdoctoral fellow at the Arizona Cancer Center.


Clinical Dx Showcase:
Labcorp

Through unparalleled diagnostics and drug development capabilities, Labcorp provides insights and accelerate innovations to improve health and improve lives.

 Speaker Profile

Ph.D., Co-Founder & CSO, BioSymetrics

Biography
Dr. Musso has a background in molecular genetics (PhD), and did post-doctoral work at Harvard Medical School and Brigham and Women's Hospital on computational and developmental biology. He spent time at a start-up working on real-time machine learning, before joining with others to start BioSymetrics with the aim of tackling the specific challenges of working with biomedical data. He was named one of the top 100 leaders in AI and drug discovery, has authored over 30 peer reviewed publications on AIML and biology.


Talk
Building Advanced Patient Diagnostic Frameworks using AI
The recent evolution of AI models has presented renewed optimism for precision medicine and disease diagnosis, but how much will truly be clinically impactful? This talk explores the development of AI-driven frameworks that integrate diverse data types, improving detection of patient sub-groups and enabling development of precision medicines in neurological disease.


Clinical Dx Showcase:
BioSymetrics

BioSymetrics uses a proprietary AI platform to analyze clinical data, scale in vivo screening, and expedite identification and development of novel therapeutics.

 Speaker Profile

M.D., Ph.D., Genomics Co-Founder, Inocras

Biography
He completed his post-doctoral research at Cancer Genome Project, Wellcome Sanger Institute (England) and published more than 80 original articles, including Nature (2023, 2021), Cell (2009), Cell Genomics (2024), Journal of Clinical Oncology (2017), and Annals of Oncology (2017). He also identified KIF5B-RET fusion oncogene in lung cancer. With the goal of revolutionizing how genomic data is used in healthcare, he innovates Inocrass genome technologies to pave the way for truly personalized precision medicine.


Talk
Inocras: Real-World Clinical Utility of Cancer Whole Genome Dx
Inocras will introduce CancerVision, its flagship target-enhanced whole genome cancer profiling Dx product, and real world insights from 1,300+ breast cancer whole genome data. This presentation will demonstrate the power of cancer whole genome Dx in the clinical and research settings.


Clinical Dx Showcase:
Inocras Inc.

Inocras is an AI-driven whole genome sequencing and bioinformatics company that specializes in cancer and rare disease. The company offers its whole genome testing products, CancerVision, MRDVision and RareVision, and provides research services for pharmaceutical, biotechnology companies and research organizations through its CAP/CLIA lab.

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by FEB. 13TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required